Global PD-1 and PD-L1 Inhibitors Market Report 2022-2026: Market is Poised to Grow by $49.34 Billion – Strategic Alliances and Expansion for Research Areas will Lead to Sizable Demand – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global PD-1 and PD-L1 Inhibitors Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.

The PD-1 and PD-L1 inhibitors market is poised to grow by $49.34 bn during 2022-2026, accelerating at a CAGR of 19.31%.

The market is driven by the increasing prevalence of cancer, the presence of patient assistance programs, and the high target affinity and specificity of pd1 and pdl1 inhibitors.

This study identifies the strong pipeline as one of the prime reasons driving the PD-1 and PD-L1 inhibitors market growth during the next few years. Also, strategic alliances and expansion for research areas in pd1 and pdl1 inhibitors will lead to sizable demand in the market.

The report on the PD-1 and PD-L1 inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The PD-1 and PD-L1 inhibitors market analysis includes application segment and geographic landscape.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading PD-1 and PD-L1 inhibitors market vendors.

Also, the PD-1 and PD-L1 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Key Topics Covered:

1 Executive Summary

1.1 Market overview

2 Market Landscape

2.1 Market ecosystem

3 Market Sizing

3.1 Market definition

3.2 Market segment analysis

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

4.1 Five forces summary

4.2 Bargaining power of buyers

4.3 Bargaining power of suppliers

4.4 Threat of new entrants

4.5 Threat of substitutes

4.6 Threat of rivalry

4.7 Market condition

5 Market Segmentation by Application

5.1 Market segments

5.2 Comparison by Application

5.3 Solid tumors – Market size and forecast 2021-2026

5.4 Blood-related tumors – Market size and forecast 2021-2026

5.5 Market opportunity by Application

6 Customer Landscape

6.1 Customer landscape overview

7 Geographic Landscape

7.1 Geographic segmentation

7.2 Geographic comparison

7.3 North America – Market size and forecast 2021-2026

7.4 Europe – Market size and forecast 2021-2026

7.5 Asia – Market size and forecast 2021-2026

7.6 Rest of World (ROW) – Market size and forecast 2021-2026

7.7 US – Market size and forecast 2021-2026

7.8 Germany – Market size and forecast 2021-2026

7.9 Canada – Market size and forecast 2021-2026

7.10 UK – Market size and forecast 2021-2026

7.11 France – Market size and forecast 2021-2026

7.12 Market opportunity by geography

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape

9.3 Landscape disruption

9.4 Industry risks

10 Vendor Analysis

10.1 Vendors covered

10.2 Market positioning of vendors

• Akeso Inc.
• Alphamab Oncology
• Amgen Inc.
• AstraZeneca Plc
• BeiGene Ltd.
• Bristol Myers Squibb Co.
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Innovent Biologics Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck and Co. Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi
• Shanghai Jhunsi Biosciences Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/wd9yj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900